10
Participants
Start Date
July 25, 2017
Primary Completion Date
April 22, 2020
Study Completion Date
April 22, 2020
Intranasal ketamine
"10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse."
Winship Cancer Institute, Atlanta
Emory University
OTHER